Editing Fastbase Solutions

==Summary==

Fastbase Solutions goal is to develop its microscopy platform, QF-Pro®, into an easy-to-use marketable healthcare product, that contributes to enhance immune-oncology treatments of cancer patients. Fastbase was founded by leading scientists from Cancer Research UK. After promising trial results,they now require funding to launch QF-Pro® commercially.

* Awarded 'best predictive test for immune oncology' by industry experts and big Pharma 
* Immune oncology is a fast-growing cancer market (16.5% CAGR)
* QF-Pro® technology is patented in all major international markets  
* We estimate that QF-Pro® could save between €25-€42k/patient in treatment costs (USA & EU)

==Idea==

<html>
<iframe width="560" height="315" src="https://player.vimeo.com/video/690851980?h=fba64b18f5" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe>
</html>

We founded Fastbase with the goal of improving the lives of cancer patients. As cancer deaths exceed 10m people per year in 2020, we are developing a solution to target one of the root causes of cancer deaths: delivering proper diagnostics.

Therefore, we have developed QF-Pro®, a molecular imaging technology that can map & quantify protein interactions & post-translational modifications in biopsies. These are important biological events. According to our research, their quantification by QF-Pro® can stratify patients for correct treatments, predict patient responses and survival. Our research indicates that no other product is currently offering a higher molecular resolution.

Traction:

* Cooperating with renowned laboratories worldwide
* Demonstrated value in predicting patient response to immune-therapies & can predict patient survival in lung & skin cancer (published in Cancer Research)
* QF-Pro® technology is protected by patents & licenses in the main markets
* Won two international awards:the EU seal of excellence & MATWIN award in 2020.

We require funding to begin our next phase: fully productising QF-Pro® & translating it to research & clinical laboratories worldwide. We believe it could improve patient outcomes of immune-oncology therapies. Our own research suggests we could expand into other diseases. The Immuno-oncology market is expected to grow at 16.5% CAGR to $37bn by 2028.

==Team==

We at FASTBASE have assembled a diverse team with an assorted range of talents & backgrounds:

'''Prof Peter J Parker: Founder & Chairman of Scientific Advisory Board'''

FASTBASE Solutions was founded by Prof Peter J Parker, a decorated scientist who is a member of the Royal Society, a Morton prize winner & recently retired from King´s College and the Francis Crick Institute, London, where he headed the Protein Phosphorylation Laboratory.

'''Mr. Fernando Aguirre (MSc): CEO'''

Fernando has significant experience in company launches, he is the founder of 8 other companies & has held roles in companies such as Ericsson, the European Commission & Hasten Ventures.

'''Dr. Veronique Calleja: CSO'''

Veronique has a strong background in cell signalling, biophysics & microscopy. With a long career in science & work undertaken in the laboratory of Prof Parker, she is perfectly placed to evolve our science & applications into the marketplace.

'''Dr. Juan Gumuzio: Operations Manager'''

Juan is an experienced operations manager who has worked in biotech operations & streamlining efficiency whilst expanding product utility.

'''Dr. James Miles (MPharmacol): Product Manager'''

James has worked with QF-Pro® for many years and has completed his doctoral studies with us. With a background in bio-imaging, molecular biology and biomedicine, he is perfectly placed to help evolve our technology into a market ready product.